Suppr超能文献

全身因素在改善糖尿病视网膜病变预后及预测糖尿病视网膜病变治疗反应中的作用

Role of Systemic Factors in Improving the Prognosis of Diabetic Retinal Disease and Predicting Response to Diabetic Retinopathy Treatment.

作者信息

Mellor Joe, Jeyam Anita, Beulens Joline W J, Bhandari Sanjeeb, Broadhead Geoffrey, Chew Emily, Fickweiler Ward, van der Heijden Amber, Gordin Daniel, Simó Rafael, Snell-Bergeon Janet, Tynjälä Anniina, Colhoun Helen

机构信息

Centre for Population Health Sciences, Usher Institute, University of Edinburgh, Edinburgh, Scotland.

Centre for Genomic & Experimental Medicine, Institute of Genetics and Cancer, University of Edinburgh, Western General Hospital Crewe Road, Edinburgh, Scotland.

出版信息

Ophthalmol Sci. 2024 Feb 17;4(4):100494. doi: 10.1016/j.xops.2024.100494. eCollection 2024 Jul-Aug.

Abstract

TOPIC

To review clinical evidence on systemic factors that might be relevant to update diabetic retinal disease (DRD) staging systems, including prediction of DRD onset, progression, and response to treatment.

CLINICAL RELEVANCE

Systemic factors may improve new staging systems for DRD to better assess risk of disease worsening and predict response to therapy.

METHODS

The Systemic Health Working Group of the Mary Tyler Moore Vision Initiative reviewed systemic factors individually and in multivariate models for prediction of DRD onset or progression (i.e., prognosis) or response to treatments (prediction).

RESULTS

There was consistent evidence for associations of longer diabetes duration, higher glycosylated hemoglobin (HbA1c), and male sex with DRD onset and progression. There is strong trial evidence for the effect of reducing HbA1c and reducing DRD progression. There is strong evidence that higher blood pressure (BP) is a risk factor for DRD incidence and for progression. Pregnancy has been consistently reported to be associated with worsening of DRD but recent studies reflecting modern care standards are lacking. In studies examining multivariate prognostic models of DRD onset, HbA1c and diabetes duration were consistently retained as significant predictors of DRD onset. There was evidence of associations of BP and sex with DRD onset. In multivariate prognostic models examining DRD progression, retinal measures were consistently found to be a significant predictor of DRD with little evidence of any useful marginal increment in prognostic information with the inclusion of systemic risk factor data apart from retinal image data in multivariate models. For predicting the impact of treatment, although there are small studies that quantify prognostic information based on imaging data alone or systemic factors alone, there are currently no large studies that quantify marginal prognostic information within a multivariate model, including both imaging and systemic factors.

CONCLUSION

With standard imaging techniques and ways of processing images rapidly evolving, an international network of centers is needed to routinely capture systemic health factors simultaneously to retinal images so that gains in prediction increment may be precisely quantified to determine the usefulness of various health factors in the prognosis of DRD and prediction of response to treatment.

FINANCIAL DISCLOSURES

Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

摘要

主题

回顾可能与更新糖尿病视网膜病变(DRD)分期系统相关的全身因素的临床证据,包括DRD发病、进展及治疗反应的预测。

临床相关性

全身因素可能改进DRD的新分期系统,以更好地评估疾病恶化风险并预测治疗反应。

方法

玛丽·泰勒·摩尔视力倡议组织的全身健康工作组分别及在多变量模型中回顾了全身因素,以预测DRD的发病或进展(即预后)或治疗反应(预测)。

结果

有一致证据表明糖尿病病程延长、糖化血红蛋白(HbA1c)升高及男性与DRD发病和进展相关。有强有力的试验证据表明降低HbA1c可降低DRD进展。有强有力的证据表明血压升高是DRD发病和进展的危险因素。一直有报道称妊娠与DRD恶化相关,但缺乏反映现代护理标准的近期研究。在研究DRD发病的多变量预后模型中,HbA1c和糖尿病病程一直是DRD发病的重要预测因素。有证据表明血压和性别与DRD发病相关。在研究DRD进展的多变量预后模型中,视网膜指标一直是DRD的重要预测因素,在多变量模型中纳入视网膜图像数据以外的全身危险因素数据后,几乎没有证据表明预后信息有任何有用的边际增加。对于预测治疗效果,尽管有少量研究仅基于影像学数据或仅基于全身因素对预后信息进行了量化,但目前尚无大型研究在多变量模型中对边际预后信息进行量化,包括影像学和全身因素。

结论

随着标准成像技术和图像处理方法的迅速发展,需要一个国际中心网络来常规地同时获取视网膜图像的全身健康因素,以便能够精确量化预测增量的获益,从而确定各种健康因素在DRD预后和治疗反应预测中的有用性。

财务披露

专有或商业披露信息可在本文末尾的脚注和披露中找到。

相似文献

1
Role of Systemic Factors in Improving the Prognosis of Diabetic Retinal Disease and Predicting Response to Diabetic Retinopathy Treatment.
Ophthalmol Sci. 2024 Feb 17;4(4):100494. doi: 10.1016/j.xops.2024.100494. eCollection 2024 Jul-Aug.
2
Rationale of Basic and Cellular Mechanisms Considered in Updating the Staging System for Diabetic Retinal Disease.
Ophthalmol Sci. 2024 Mar 27;4(5):100521. doi: 10.1016/j.xops.2024.100521. eCollection 2024 Sep-Oct.
3
Measuring Quality of Life in Diabetic Retinal Disease: A Narrative Review of Available Patient-Reported Outcome Measures.
Ophthalmol Sci. 2023 Aug 9;4(2):100378. doi: 10.1016/j.xops.2023.100378. eCollection 2024 Mar-Apr.
4
Imaging Modalities for Assessing the Vascular Component of Diabetic Retinal Disease: Review and Consensus for an Updated Staging System.
Ophthalmol Sci. 2023 Dec 10;4(3):100449. doi: 10.1016/j.xops.2023.100449. eCollection 2024 May-Jun.
5
Visual Function Measurements in Eyes With Diabetic Retinopathy: An Expert Opinion on Available Measures.
Ophthalmol Sci. 2024 Apr 6;4(5):100519. doi: 10.1016/j.xops.2024.100519. eCollection 2024 Sep-Oct.
6
Prognostic factors for the development and progression of proliferative diabetic retinopathy in people with diabetic retinopathy.
Cochrane Database Syst Rev. 2023 Feb 22;2(2):CD013775. doi: 10.1002/14651858.CD013775.pub2.
7
Report From the 2022 Mary Tyler Moore Vision Initiative Diabetic Retinal Disease Clinical Endpoints Workshop.
Transl Vis Sci Technol. 2023 Nov 1;12(11):33. doi: 10.1167/tvst.12.11.33.
9
Standardization of Optical Coherence Tomography Angiography Imaging Biomarkers in Diabetic Retinal Disease.
Ophthalmic Res. 2021;64(6):871-887. doi: 10.1159/000518620. Epub 2021 Jul 30.
10
Integrative Biology of Diabetic Retinal Disease: Lessons from Diabetic Kidney Disease.
J Clin Med. 2021 Mar 18;10(6):1254. doi: 10.3390/jcm10061254.

引用本文的文献

1
Diabetic retinal disease.
Nat Rev Dis Primers. 2025 Aug 28;11(1):62. doi: 10.1038/s41572-025-00646-x.
2
Report of the 2023 Mary Tyler Moore Vision Initiative Workshop.
Transl Vis Sci Technol. 2025 Jul 1;14(7):11. doi: 10.1167/tvst.14.7.11.
3
Predictive Value of Bone Metabolism Marker PINP in the Risk of Diabetic Retinopathy: A Cross-Sectional Study.
Diabetes Metab Syndr Obes. 2025 May 29;18:1801-1808. doi: 10.2147/DMSO.S518629. eCollection 2025.
5
Renal dysfunction associated with clinical response to intravitreal conbercept therapy for diabetic macular edema.
Int J Ophthalmol. 2025 Mar 18;18(3):454-461. doi: 10.18240/ijo.2025.03.12. eCollection 2025.

本文引用的文献

1
Abridged for Primary Care Providers.
Clin Diabetes. 2022 Winter;41(1):4-31. doi: 10.2337/cd23-as01. Epub 2022 Dec 12.
3
Optical Coherence Tomography Biomarkers in Bilateral Diabetic Macular Edema Patients with Asymmetric anti-VEGF Response.
Semin Ophthalmol. 2021 Aug 18;36(5-6):444-451. doi: 10.1080/08820538.2021.1907423. Epub 2021 Mar 29.
5
The effect of insulin pump therapy in retinal vasculature in type 1 diabetic patients.
Eur J Ophthalmol. 2021 Nov;31(6):3142-3148. doi: 10.1177/1120672121990576. Epub 2021 Jan 26.
6
Clinical Impact of Residual C-Peptide Secretion in Type 1 Diabetes on Glycemia and Microvascular Complications.
Diabetes Care. 2021 Feb;44(2):390-398. doi: 10.2337/dc20-0567. Epub 2020 Dec 10.
7
11. Microvascular Complications and Foot Care: .
Diabetes Care. 2021 Jan;44(Suppl 1):S151-S167. doi: 10.2337/dc21-S011.
9
Socioeconomic deprivation and development of diabetic retinopathy in patients with type 1 diabetes mellitus.
BMJ Open Diabetes Res Care. 2020 Nov;8(2). doi: 10.1136/bmjdrc-2020-001387.
10
Bacterial infections as novel risk factors of severe diabetic retinopathy in individuals with type 1 diabetes.
Br J Ophthalmol. 2021 Aug;105(8):1104-1110. doi: 10.1136/bjophthalmol-2020-316202. Epub 2020 Sep 14.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验